JBIO
Jade Biosciences, Inc.
Biotechnology
Market Cap$525M
5Y Perf.-98.1%
Build Your Comparison
Side-by-side financial analysisJBIO
RCUS
Try popular comparisons:
Stock Comparison
JBIO vs RCUS
Revenue, margins, valuation, and 5-year total return — side by side.
RCUS
Arcus Biosciences, Inc.
Biotechnology
Market Cap$2.35B
5Y Perf.-7.7%
JBIO vs RCUS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  JBIO |  RCUS |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $525M | $2.35B |
| Revenue (TTM) | $0.00 | $236M |
| Net Income (TTM) | $-130M | $-369M |
| Gross Margin | — | 90.7% |
| Operating Margin | — | -168.6% |
| Total Debt | $724K | $99M |
| Cash & Equiv. | $88M | $222M |
JBIO vs RCUS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
JBIO
RCUS
| Stock | Jun 21 | Jun 26 | Return |
|---|---|---|---|
| Jade Biosciences, I… (JBIO) | 100 | 1.9 | -98.1% |
| Arcus Biosciences, … (RCUS) | 100 | 92.3 | -7.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: JBIO vs RCUS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: JBIO leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Arcus Biosciences, Inc. is the stronger pick specifically for recent price momentum and sentiment and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
🥇JBIO emerged as the overall leader. Track its performance:
JBIO
Jade Biosciences, Inc.
The Income Pick
JBIO carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 1 yrs, beta 1.61
- EPS growth 95.2%
- Lower volatility, beta 1.61, Low D/E 0.2%, current ratio 20.33x
Best for: income & stability and growth exposure
RCUS
Arcus Biosciences, Inc.
The Long-Run Compounder
RCUS is the clearest fit if your priority is long-term compounding.
- 37.1% 10Y total return vs JBIO's -97.7%
- +156.6% vs JBIO's +128.7%
- -35.3% ROA vs JBIO's -47.3%, ROIC -64.1% vs -59.2%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth |  JBIO | 141.8% revenue growth vs RCUS's -4.3% |
| Quality / Margins | JBIO | 2.2% margin vs RCUS's -156.4% |
| Stability / Safety | JBIO | Beta 1.61 vs RCUS's 1.98, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) |  RCUS | +156.6% vs JBIO's +128.7% |
| Efficiency (ROA) | RCUS | -35.3% ROA vs JBIO's -47.3%, ROIC -64.1% vs -59.2% |
JBIO vs RCUS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
JBIO vs RCUS — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLJBIOLAGGINGRCUS
RCUSArcus Biosciences, In…
1leads
JBIOJade Biosciences, Inc.
1leads
6 Total Categories
CATEGORYLEADERvs RCUSMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
—
—
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
JBIO5/8
Total Returns1Y, 3Y, 5Y total returns with dividends
RCUS5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
Insufficient data to determine a leader in this category.
Income & Cash Flow (Last 12 Months)
RCUS and JBIO operate at a comparable scale, with $236M and $0 in trailing revenue.
| Metric | JBIOJade Biosciences,… | RCUSArcus Biosciences… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $236M |
| EBITDAEarnings before interest/tax | -$134M | -$391M |
| Net IncomeAfter-tax profit | -$130M | -$369M |
| Free Cash FlowCash after capex | -$117M | -$489M |
| Gross MarginGross profit ÷ Revenue | — | +90.7% |
| Operating MarginEBIT ÷ Revenue | — | -168.6% |
| Net MarginNet income ÷ Revenue | — | -156.4% |
| FCF MarginFCF ÷ Revenue | — | -2.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -39.3% |
| EPS Growth (YoY)Latest quarter vs prior year | — | +10.5% |
Insufficient data to determine a leader in this category.
Valuation Metrics
Evenly matched — JBIO and RCUS each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | JBIOJade Biosciences,… | RCUSArcus Biosciences… |
|---|---|---|
| Market CapShares × price | $525M | $2.3B |
| Enterprise ValueMkt cap + debt − cash | $437M | $2.2B |
| Trailing P/EPrice ÷ TTM EPS | -3.96x | -7.08x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 9.50x |
| Price / BookPrice ÷ Book value/share | 1.52x | 3.97x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — JBIO and RCUS each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
JBIO leads this category, winning 5 of 8 comparable metrics.
Profitability & Efficiency
JBIO delivers a -51.3% return on equity — every $100 of shareholder capital generates $-51 in annual profit, vs $-69 for RCUS. JBIO carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to RCUS's 0.16x. On the Piotroski fundamental quality scale (0–9), JBIO scores 3/9 vs RCUS's 0/9, reflecting mixed financial health.
| Metric | JBIOJade Biosciences,… | RCUSArcus Biosciences… |
|---|---|---|
| ROE (TTM)Return on equity | -51.3% | -69.0% |
| ROA (TTM)Return on assets | -47.3% | -35.3% |
| ROICReturn on invested capital | -59.2% | -64.1% |
| ROCEReturn on capital employed | -55.4% | -42.1% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 0 |
| Debt / EquityFinancial leverage | 0.00x | 0.16x |
| Net DebtTotal debt minus cash | -$88M | -$123M |
| Cash & Equiv.Liquid assets | $88M | $222M |
| Total DebtShort + long-term debt | $724,000 | $99M |
| Interest CoverageEBIT ÷ Interest expense | — | -13.38x |
JBIO leads this category, winning 5 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
RCUS leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in RCUS five years ago would be worth $9,361 today (with dividends reinvested), compared to $231 for JBIO. Over the past 12 months, RCUS leads with a +156.6% total return vs JBIO's +128.7%. The 3-year compound annual growth rate (CAGR) favors RCUS at 5.0% vs JBIO's -67.7% — a key indicator of consistent wealth creation.
| Metric | JBIOJade Biosciences,… | RCUSArcus Biosciences… |
|---|---|---|
| YTD ReturnYear-to-date | +13.6% | +0.0% |
| 1-Year ReturnPast 12 months | +128.7% | +156.6% |
| 3-Year ReturnCumulative with dividends | -96.6% | +15.9% |
| 5-Year ReturnCumulative with dividends | -97.7% | -6.4% |
| 10-Year ReturnCumulative with dividends | -97.7% | +37.1% |
| CAGR (3Y)Annualised 3-year return | -67.7% | +5.0% |
RCUS leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — JBIO and RCUS each lead in 1 of 2 comparable metrics.
Risk & Volatility
JBIO is the less volatile stock with a 1.61 beta — it tends to amplify market swings less than RCUS's 1.98 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. RCUS currently trades 81.1% from its 52-week high vs JBIO's 57.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | JBIOJade Biosciences,… | RCUSArcus Biosciences… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.61x | 1.98x |
| 52-Week HighHighest price in past year | $27.96 | $28.72 |
| 52-Week LowLowest price in past year | $6.57 | $7.91 |
| % of 52W HighCurrent price vs 52-week peak | +57.5% | +81.1% |
| RSI (14)Momentum oscillator 0–100 | 26.8 | 39.3 |
| Avg Volume (50D)Average daily shares traded | 813K | 1.1M |
Evenly matched — JBIO and RCUS each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates JBIO as "Buy" and RCUS as "Buy". Consensus price targets imply 174.9% upside for JBIO (target: $44) vs 33.8% for RCUS (target: $31).
| Metric | JBIOJade Biosciences,… | RCUSArcus Biosciences… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $44.20 | $31.17 |
| # AnalystsCovering analysts | 4 | 18 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 1 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
JBIO leads in 1 of 6 categories (Profitability & Efficiency). RCUS leads in 1 (Total Returns). 2 tied.
Best OverallJade Biosciences, Inc. (JBIO)Leads 1 of 6 categories
Loading custom metrics...
JBIO vs RCUS: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is JBIO or RCUS a better buy right now?
Analysts rate Jade Biosciences, Inc.
(JBIO) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — JBIO or RCUS?
Over the past 5 years, Arcus Biosciences, Inc.
(RCUS) delivered a total return of -6. 4%, compared to -97. 7% for Jade Biosciences, Inc. (JBIO). Over 10 years, the gap is even starker: RCUS returned +37. 1% versus JBIO's -97. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — JBIO or RCUS?
By beta (market sensitivity over 5 years), Jade Biosciences, Inc.
(JBIO) is the lower-risk stock at 1. 61β versus Arcus Biosciences, Inc. 's 1. 98β — meaning RCUS is approximately 23% more volatile than JBIO relative to the S&P 500. On balance sheet safety, Jade Biosciences, Inc. (JBIO) carries a lower debt/equity ratio of 0% versus 16% for Arcus Biosciences, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — JBIO or RCUS?
On earnings-per-share growth, the picture is similar: Jade Biosciences, Inc.
grew EPS 95. 2% year-over-year, compared to -4. 8% for Arcus Biosciences, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — JBIO or RCUS?
Jade Biosciences, Inc.
(JBIO) is the more profitable company, earning 0. 0% net margin versus -142. 9% for Arcus Biosciences, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JBIO leads at 0. 0% versus -156. 3% for RCUS. At the gross margin level — before operating expenses — RCUS leads at 96. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — JBIO or RCUS?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is JBIO or RCUS better for a retirement portfolio?
For long-horizon retirement investors, Jade Biosciences, Inc.
(JBIO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Arcus Biosciences, Inc. (RCUS) carries a higher beta of 1. 98 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (JBIO: -97. 7%, RCUS: +37. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between JBIO and RCUS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.